| 000 | 01697 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517031603.0 | ||
| 264 | 0 | _c20151001 | |
| 008 | 201510s 0 0 eng d | ||
| 022 | _a0946-1965 | ||
| 024 | 7 |
_a10.5414/CP202112 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKousar, Shazia | |
| 245 | 0 | 0 |
_aClinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology and therapeutics _cJul 2015 |
||
| 300 |
_a504-16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Validation Study | ||
| 650 | 0 | 4 |
_aAnticonvulsants _xadverse effects |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C9 _xgenetics |
| 650 | 0 | 4 |
_aEpilepsy _xdrug therapy |
| 650 | 0 | 4 | _aGene Frequency |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIndia |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPharmacovigilance |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aPhenytoin _xadverse effects |
| 650 | 0 | 4 | _aPolymerase Chain Reaction |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aPolymorphism, Restriction Fragment Length |
| 700 | 1 | _aWafai, Zahoor A | |
| 700 | 1 | _aWani, Mushtaq A | |
| 700 | 1 | _aJan, Tariq R | |
| 700 | 1 | _aAndrabi, Khurshid I | |
| 773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 53 _gno. 7 _gp. 504-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5414/CP202112 _zAvailable from publisher's website |
| 999 |
_c24870502 _d24870502 |
||